deucravacitinib,zasocitinib,apremilast
takeda,bms,amgen
['psoriasis', 'tak-279', 'sotyktu', 'takeda', 'bms']
. points to high level of complete skin clearance in phase 2b trial of tyk2 inhibitor tak-279 in #psoriasis at #aad23, as it plays catch up with bms sotyktu 
https://t.co/O0ZJQGuINh, and its digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate